Therapeutic plasma exchange has emerged from a niche autoimmune treatment into a flagship longevity procedure offered by elite clinics. Here's what the heterochronic parabiosis research actually showed, what TPE does in humans, and whether the $5,000–15,000 cost is justified.
In 2005, Conboy et al. published a paper in *Nature* showing that surgically connecting the circulatory systems of young and old mice (heterochronic parabiosis) rejuvenated the older mouse's tissues. Specifically, old muscle stem cells regained the capacity to repair damaged muscle, old liver tissue reactivated juvenile gene expression patterns, and old neural progenitor cells resumed dividing. The implication was striking: there are circulating factors in young blood that maintain youthful tissue function, and removing those factors (or replacing them) might be a tractable longevity intervention.
Two decades later, therapeutic plasma exchange (TPE) — replacing a substantial fraction of a patient's plasma with donor plasma or albumin solution — has become the most popular elite longevity clinic procedure based on this hypothesis. This article reviews what the research actually shows in humans, what TPE does mechanistically, the costs, and how to evaluate whether the procedure is worth the very substantial price.
The Conboy mouse experiments were striking but specifically demonstrated that young blood factors rejuvenated old tissue. Subsequent work by the same group revealed an asymmetric effect: removing aging-promoting factors from old blood was nearly as beneficial as adding youth factors. This led to the dilution hypothesis — that the age-related increase in pro-inflammatory and senescence-promoting circulating factors may be the primary driver of systemic aging, and that diluting these factors (without replacement with young blood) might capture much of the benefit.
A landmark 2020 paper by the Conboy group showed that simple plasma exchange with saline + albumin in old mice produced rejuvenation comparable to true heterochronic parabiosis. This is the scientific foundation for human TPE protocols.
TPE is a clinical procedure used for decades in autoimmune disease (myasthenia gravis, Guillain-Barré, ANCA vasculitis, TTP). Mechanically: a needle in one arm draws blood through an apheresis machine, which separates plasma from cellular components. The plasma is discarded; the cellular components are returned to the patient mixed with replacement fluid (typically 5% albumin solution, sometimes fresh frozen plasma).